All In Biotech

Drug Trial Radar · NCT05610813

Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back Pain

Multicentre, Randomized, Open-label Study to Prove an Additional Benefit of the Full-spectrum Cannabis Extract VER-01 Over Opioids in the Treatment of Patients With Chronic Non-specific Low Back Pain

Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 384 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

384

Actual

Start

Jun 8, 2023

Primary completion

Oct 18, 2024

Study completion Oct 18, 2024

Sponsor

Lead sponsor
Vertanical GmbHIndustry
Sponsor type
Industry
First posted
Nov 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Randomized, open-label, parallel-group phase III trial to prove an additional benefit of the full-spectrum cannabis extract VER-01 over opioids in patients with chronic non-specific low back pain for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

Conditions

  • Chronic Non-specific Low Back Pain

Interventions

  • VER-01Drug

    Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype (cannabis leaves and - flowers), corresponding to 21 mg (-)-trans-Δ9-Tetra-hydrocannabinol (THC) per gram drug product

  • Opioid therapyDrug

    The patient-specific selection of the marketed opioid (based on standard of care and provided for this study) is at the discretion of the investigator and made at Visit 1, i.e., before randomization at Visit 2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Risk of developing constipationTime frame: 190 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Rheumazentrum Prof. Dr. med. Gunther Neeck

    Bad Doberan, Germany

  • Medizinische Hochschule Hannover (MHH)

    Hanover, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.